Literature DB >> 20578254

Interleukin-28B genetic variants and hepatitis virus infection by different viral genotypes.

Marco Antonio Montes-Cano1, José Raúl García-Lozano, Cristina Abad-Molina, Manuel Romero-Gómez, Natalia Barroso, José Aguilar-Reina, Antonio Núñez-Roldán, María Francisca González-Escribano.   

Abstract

UNLABELLED: Genetic host factors may modify the course of the hepatitis C virus (HCV) infection. Very recently, a genome-wide scan that reported association of the IL28B locus with response to treatment in HCV infection was published. The aim of the current study was to investigate the relationship of this locus with outcome of HCV infection in a cohort constituted by a total of 731 Spanish individuals. From these, 284 were subjects with persistent infection, 69 were individuals who naturally cleared the virus, and 378 were noninfected subjects. Genotyping of the rs12979860 (C>T) in the IL28B locus was performed using a TaqMan 5' allelic discrimination assay. The CC genotype was overrepresented among patients infected with viral genotypes non-1 (66.7% versus 39.1% in patients infected with viral genotype-1, P = 8.5 x 10(-5), odds ratio [OR] = 0.32, 95% confidence interval [CI] 0.17-0.60); patients with spontaneous resolution of infection (72.5% versus 45.6% of the individuals with persistent infection, P = 6.2 x 10(-5), OR = 0.32; 95%CI, 0.18-0.57); and lastly, patients with sustained response (60.2% versus 32.1% found in patients with nonsustained response, P = 3.1 x 10(-5), OR = 0.31; 95%CI, 0.17-0.56).
CONCLUSION: We have found different rates of viral genotype infection depending on the IL28B variant as well as an association of this locus with natural and treatment-mediated response.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20578254     DOI: 10.1002/hep.23624

Source DB:  PubMed          Journal:  Hepatology        ISSN: 0270-9139            Impact factor:   17.425


  67 in total

1.  Frequency of interleukin 28B rs12979860 C>T variants in Filipino patients chronically infected with hepatitis B virus.

Authors:  Michael O Baclig; Karen G Reyes; Cynthia A Mapua; Juliet Gopez-Cervantes; Filipinas F Natividad
Journal:  Mol Biol Rep       Date:  2014-11-13       Impact factor: 2.316

2.  IL28B polymorphisms influence stage of fibrosis and spontaneous or interferon-induced viral clearance in thalassemia patients with hepatitis C virus infection.

Authors:  Vito Di Marco; Fabrizio Bronte; Vincenza Calvaruso; Marcello Capra; Zelia Borsellino; Aurelio Maggio; Maria Concetta Renda; Lorella Pitrolo; Maria Carmela Lo Pinto; Michele Rizzo; Flavia Fiorenza; Calogera Gerardi; Stefania Grimaudo; Antonietta Di Cristina; Massimo Levrero; Antonio Craxì
Journal:  Haematologica       Date:  2011-12-16       Impact factor: 9.941

Review 3.  Genetics of IL28B and HCV--response to infection and treatment.

Authors:  C Nelson Hayes; Michio Imamura; Hiroshi Aikata; Kazuaki Chayama
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2012-05-29       Impact factor: 46.802

4.  Role of serum level and genetic variation of IL-28B in interferon responsiveness and advanced liver disease in chronic hepatitis C patients.

Authors:  Abdolvahab Alborzi; Tayebeh Hashempour; Javad Moayedi; Zahra Musavi; Gholamreza Pouladfar; Shahin Merat
Journal:  Med Microbiol Immunol       Date:  2017-02-18       Impact factor: 3.402

5.  Interleukin-28 and hepatitis C virus genotype-4: treatment-induced clearance and liver fibrosis.

Authors:  Moutaz Derbala; Nasser Rizk; Fatima Shebl; Saad Alkaabi; Nazeeh Eldweik; Anil John; Manik Sharma; Rafie Yaqoob; Muneera Almohanadi; Mohammed Butt; Khaled Alejji
Journal:  World J Gastroenterol       Date:  2012-12-21       Impact factor: 5.742

6.  Clinical Pharmacogenetics Implementation Consortium (CPIC) guidelines for IFNL3 (IL28B) genotype and PEG interferon-α-based regimens.

Authors:  A J Muir; L Gong; S G Johnson; M T M Lee; M S Williams; T E Klein; K E Caudle; D R Nelson
Journal:  Clin Pharmacol Ther       Date:  2013-10-04       Impact factor: 6.875

Review 7.  Individualization of chronic hepatitis C treatment according to the host characteristics.

Authors:  Nikolaos K Gatselis; Kalliopi Zachou; Asterios Saitis; Maria Samara; George N Dalekos
Journal:  World J Gastroenterol       Date:  2014-03-21       Impact factor: 5.742

8.  Two IL28B polymorphisms are associated with the treatment response of different genotypes of hepatitis C in different racial populations: A meta-analysis.

Authors:  Li-Sheng Wu; Hong Wang; Xiao-Ping Geng
Journal:  Exp Ther Med       Date:  2011-11-21       Impact factor: 2.447

9.  Association of IL28B genotype with fibrosis progression and clinical outcomes in patients with chronic hepatitis C: a longitudinal analysis.

Authors:  Mazen Noureddin; Elizabeth C Wright; Harvey J Alter; Shauna Clark; Emmanuel Thomas; Richard Chen; Xiongce Zhao; Cathy Conry-Cantilena; David E Kleiner; T Jake Liang; Marc G Ghany
Journal:  Hepatology       Date:  2013-09-30       Impact factor: 17.425

10.  Interleukin 28B Polymorphisms and Hepatitis C-Translating the Association into Clinical Decision Making.

Authors:  Col Pankaj Puri
Journal:  J Clin Exp Hepatol       Date:  2011-08-26
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.